Structures by: Milić D.
Total: 26
Ethoxo-oxo-(salicylaldehydehyde 4-phenylthiosemicarbazonato(2- ))vanadium(V)
C16H16N3O3SV
Dalton Transactions (2009) 44 9914-9923
a=10.8123(2)Å b=9.8588(2)Å c=16.0968(4)Å
α=90.00° β=102.663(2)° γ=90.00°
Oxo-propoxo-(salicylaldehyde 4-phenylthiosemicarbazonato(2- ))vanadium(V)
C17H18N3O3SV
Dalton Transactions (2009) 44 9914-9923
a=15.1837(4)Å b=8.0325(2)Å c=16.0582(5)Å
α=90.00° β=114.404(4)° γ=90.00°
Diethoxo-μ-oxo-dioxobis[2-(5-phenylamino-[1,3,4]thiadiazol-2-yl)-phenolato]divanadium(V)
C32H30N6O7S2V2
Dalton Transactions (2009) 44 9914-9923
a=11.4910(9)Å b=11.8518(9)Å c=14.7813(13)Å
α=92.462(7)° β=100.455(7)° γ=118.288(8)°
Dimethoxo-μ-oxo-dioxobis[2-(5-phenylamino-[1,3,4]thiadiazol-2-yl)-phenolato]divanadium(V) methanol hemisolvate
C30H26N6O7S2V2,0.5(CH4O)
Dalton Transactions (2009) 44 9914-9923
a=11.8680(19)Å b=11.963(2)Å c=14.3202(9)Å
α=102.100(10)° β=96.852(8)° γ=119.640(19)°
Diethoxo-μ-oxo-dioxobis[2-(5-phenylamino-[1,3,4]thiadiazol-2-yl)-phenolato]divanadium(V) ethanol hemisolvate
C32H30N6O7S2V2,0.5(C2H6O)
Dalton Transactions (2009) 44 9914-9923
a=11.6448(4)Å b=12.1611(4)Å c=14.4691(5)Å
α=73.441(3)° β=84.791(3)° γ=62.827(3)°
Μ-oxo-dioxobis[2-(5-phenylamino-[1,3,4]thiadiazol-2-yl)-phenolato]-dipropoxo-divanadium(V) propanol hemisolvate
C34H34N6O7S2V2,0.5(C3H8O)
Dalton Transactions (2009) 44 9914-9923
a=13.4762(5)Å b=17.2325(7)Å c=17.0544(6)Å
α=90.00° β=101.835(4)° γ=90.00°
C17H30N4Pt
C17H30N4Pt
Dalton transactions (Cambridge, England : 2003) (2011) 40, 37 9362-9365
a=11.5536(2)Å b=18.5617(3)Å c=8.6213(2)Å
α=90.00° β=90.00° γ=90.00°
C38H76Ag2Br2N8Pt4S2,3(C3H6O)
C38H76Ag2Br2N8Pt4S2,3(C3H6O)
Dalton transactions (Cambridge, England : 2003) (2011) 40, 37 9362-9365
a=9.8360(3)Å b=12.2936(4)Å c=13.7271(4)Å
α=74.311(3)° β=85.741(2)° γ=79.721(3)°
C16H24N4O3Pt,3(H2O)
C16H24N4O3Pt,3(H2O)
Dalton transactions (Cambridge, England : 2003) (2011) 40, 37 9362-9365
a=8.8501(2)Å b=17.2896(4)Å c=13.1079(2)Å
α=90.00° β=94.015(2)° γ=90.00°
Bis(μ-Chloro)-bis(N-benzyl-N-((2-pyridin-2-yl)methyl)oxalamidato-N,N'',O)- di-copper(II)
C30H28Cl2Cu2N6O4
Dalton transactions (Cambridge, England : 2003) (2014) 43, 31 11877-11887
a=7.7369(3)Å b=9.8930(3)Å c=21.9325(10)Å
α=90.00° β=101.955(4)° γ=90.00°
Bis(μ-Bromo)-bis(N-benzyl-N-((2-pyridin-2-yl)methyl)oxalamidato-N,N'',O)- di-copper(II)
C30H28Br2Cu2N6O4
Dalton transactions (Cambridge, England : 2003) (2014) 43, 31 11877-11887
a=8.0988(6)Å b=9.6585(6)Å c=10.1449(6)Å
α=93.172(5)° β=90.749(5)° γ=94.721(5)°
Bis(μ-Bromo)-bis(N-(L-leucine)-N-(pyridin-2-ylmethyl)oxalamidato-N,N'',O)- di-copper(II)
C30H40Br2Cu2N6O8
Dalton transactions (Cambridge, England : 2003) (2014) 43, 31 11877-11887
a=8.4814(3)Å b=9.3314(4)Å c=11.7613(3)Å
α=81.072(3)° β=78.321(3)° γ=76.097(4)°
Caesium chloride 2-(N-morpholinio)ethanesulfonate
Cs,Cl,C6H13NO4S
Acta Crystallographica Section E (2005) 61, 4 m757-m758
a=12.110(2)Å b=8.1753(15)Å c=12.566(2)Å
α=90.00° β=111.963(17)° γ=90.00°
Ethyl 1-ethyl-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylate
C14H14INO3
Acta Crystallographica Section C (2009) 65, 10 o512-o516
a=10.8169(3)Å b=8.0588(2)Å c=15.8422(4)Å
α=90.00° β=91.326(3)° γ=90.00°
Ethyl 1-cyclopropyl-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylate
C15H14INO3
Acta Crystallographica Section C (2009) 65, 10 o512-o516
a=10.8406(2)Å b=8.2843(2)Å c=15.9269(3)Å
α=90.00° β=93.127(2)° γ=90.00°
Ethyl 1-(dimethylamino)-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylate
C14H15IN2O3
Acta Crystallographica Section C (2009) 65, 10 o512-o516
a=10.8437(3)Å b=9.9660(2)Å c=14.4482(4)Å
α=90.00° β=108.436(3)° γ=90.00°
C65H56Ag2N4O1P2Pt2,4(C3H6O),2(BF4)
C65H56Ag2N4O1P2Pt2,4(C3H6O),2(BF4)
Inorganic Chemistry (2010) 49, 2721-2726
a=23.2342(13)Å b=18.1759(12)Å c=17.5809(12)Å
α=90.00° β=96.314(10)° γ=90.00°
1-{2-[(2-Hydroxy-4-methoxy-benzylidene)-hydrazono]-4-methyl-3-phenyl- -2,3-dihydro-thiazol-5-yl}-ethanone
C20H19N3O3S
Crystal Growth & Design (2011) 11, 12 5227
a=9.5280(4)Å b=10.0721(4)Å c=10.5449(3)Å
α=95.344(3)° β=110.811(4)° γ=95.371(4)°
Ethoxo-(4-methoxysalicylaldehyde-4-phenylthiosemicarbazonato(2-))- oxo-vanadium(V)
C17H18N3O4SV
Crystal Growth & Design (2011) 11, 12 5227
a=12.4255(3)Å b=15.7746(4)Å c=18.5559(5)Å
α=90.00° β=96.510(2)° γ=90.00°
Propoxo-(4-methoxysalicylaldehyde-4-phenylthiosemicarbazonato(2-))- oxo-vanadium(V)
C18H20N3O4SV
Crystal Growth & Design (2011) 11, 12 5227
a=12.3684(3)Å b=15.9862(4)Å c=19.1848(5)Å
α=90.00° β=97.975(2)° γ=90.00°
Propoxo-(4-methoxysalicylaldehyde-4-phenylthiosemicarbazonato(2-))- oxo-vanadium(V)
C18H20N3O4SV
Crystal Growth & Design (2011) 11, 12 5227
a=9.7545(11)Å b=12.9941(14)Å c=30.452(3)Å
α=88.183(8)° β=80.838(9)° γ=89.875(9)°
Methoxo-(4-methoxysalicylaldehyde-4-phenylthiosemicarbazonato(2-))- oxo-vanadium(V)
C16H16N3O4SV
Crystal Growth & Design (2011) 11, 12 5227
a=12.2897(5)Å b=10.3757(4)Å c=16.3811(9)Å
α=90.00° β=125.598(3)° γ=90.00°
Ethoxo-(4-methoxysalicylaldehyde-4-phenylthiosemicarbazonato(2-))- oxo-vanadium(V)
C17H18N3O4SV
Crystal Growth & Design (2011) 11, 12 5227
a=7.2239(11)Å b=9.693(2)Å c=13.592(3)Å
α=87.323(18)° β=86.732(15)° γ=71.447(17)°
Aquabis(L-isoleucinato)copper(II)
C12H26CuN2O5
Crystal Growth & Design (2012) 12, 8 4116
a=7.5799(15)Å b=9.4213(19)Å c=21.537(4)Å
α=90.00° β=90.00° γ=90.00°
Cis aquabis(L-isoleucinato-N,O)copper(II)
C12H26CuN2O5
Crystal Growth & Design (2012) 12, 8 4116
a=23.2551(14)Å b=9.4928(4)Å c=7.5418(4)Å
α=90.00° β=107.560(6)° γ=90.00°
Cis aquabis(L-isoleucinato-N,O)copper(II)
C12H26CuN2O5
Crystal Growth & Design (2012) 12, 8 4116
a=22.5755(5)Å b=9.44266(17)Å c=7.46733(15)Å
α=90.00° β=106.250(2)° γ=90.00°